Table 4. . Baseline comorbidities/conditions.
| Variable | Bupropion (n = 11,835) | Citalopram (n = 21,446) | Duloxetine (n = 14,161) | Escitalopram (n = 11,695) | Fluoxetine (n = 7604) | Mirtazapine (n = 17,368) | Paroxetine (n = 5621) | Sertraline (n = 44,848) | Venlafaxine (n = 7560) | p-value | Standardized difference |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age mean (SD) | 67.7 (6.50) | 70.14 (8.36) | 69.76 (7.52) | 71.37 (8.31) | 68.77 (7.25) | 72.67 (9.22) | 70.09 (7.68) | 70.88 (8.14) | 69.3 (7.53) | <0.001 | 0.622 |
| Charlson comorbidity index | 1.07 (1.56) | 1.22 (1.68) | 1.51 (1.98) | 1.23 (1.76) | 1.05 (1.53) | 1.65 (2.26) | 1.06 (1.57) | 1.31 (1.81) | 1.19 (1.72) | <0.001 | 0.309 |
| Index year (median) | 2018 | 2009 | 2019 | 2019 | 2017 | 2017 | 2014 | 2017 | 2016 | <0.001 | 1.888 |
| Race | |||||||||||
| Black | 1743 (14.7%) | 2492 (11.6%) | 2422 (17.1%) | 1693 (14.5%) | 873 (11.5%) | 3799 (21.9%) | 594 (10.6%) | 7222 (16.1%) | 746 (9.9%) | <0.001 | 0.332 |
| Other/unk. | 1163 (9.8%) | 2887 (13.5%) | 1524 (10.8%) | 1165 (10.0%) | 978 (12.9%) | 2082 (12.0%) | 842 (15.0%) | 4993 (11.1%) | 893 (11.8%) | ||
| White | 8929 (75.4%) | 16,067 (74.9%) | 10,215 (72.1%) | 8837 (75.6%) | 5753 (75.7%) | 11487 (66.1%) | 4185 (74.5%) | 32,633 (72.8%) | 5921 (78.3%) | ||
| Sex, female | 659 (5.568%) | 672 (3.133%) | 962 (6.793%) | 659 (5.635%) | 419 (5.51%) | 451 (2.597%) | 225 (4.003%) | 1569 (3.498%) | 461 (6.098%) | <0.001 | 0.199 |
| Sex, male | 11,176 (94.432%) | 20,774 (96.867%) | 13,199 (93.207%) | 11,036 (94.365%) | 7185 (94.49%) | 16917 (97.403%) | 5396 (95.997%) | 43,279 (96.502%) | 7099 (93.902%) | ||
| BMI | |||||||||||
| <18.5 | 141 (1.2%) | 302 (1.4%) | 128 (0.9%) | 122 (1.0%) | 68 (0.9%) | 798 (4.6%) | 80 (1.4%) | 538 (1.2%) | 71 (0.9%) | ||
| 18.5–24.9 | 2311 (19.5%) | 4640 (21.6%) | 2237 (15.8%) | 2322 (19.9%) | 1339 (17.6%) | 6313 (36.3%) | 1193 (21.2%) | 9093 (20.3%) | 1350 (17.9%) | ||
| 25–29.9 | 4088 (34.5%) | 7967 (37.1%) | 4663 (32.9%) | 4273 (36.5%) | 2688 (35.4%) | 6099 (35.1%) | 2132 (37.9%) | 16,651 (37.1%) | 2695 (35.6%) | <0.001 | 0.576 |
| 30+ | 5185 (43.8%) | 8347 (38.9%) | 7001 (49.4%) | 4822 (41.2%) | 3416 (44.9%) | 3968 (22.8%) | 2154 (38.3%) | 18,093 (40.3%) | 3346 (44.3%) | ||
| Missing | 110 (0.9%) | 190 (0.9%) | 132 (0.9%) | 156 (1.3%) | 93 (1.2%) | 190 (1.1%) | 62 (1.1%) | 473 (1.1%) | 98 (1.3%) | ||
| ADHD | 223 (1.9%) | 50 (0.2%) | 70 (0.5%) | 54 (0.5%) | 40 (0.5%) | 51 (0.3%) | 7 (0.1%) | 123 (0.3%) | 48 (0.6%) | <0.001 | 0.181 |
| Drug abuse | 485 (4.1%) | 500 (2.3%) | 527 (3.7%) | 316 (2.7%) | 244 (3.2%) | 971 (5.6%) | 129 (2.3%) | 1334 (3.0%) | 240 (3.2%) | <0.001 | 0.170 |
| Alcohol abuse | 1056 (8.9%) | 1555 (7.3%) | 902 (6.4%) | 839 (7.2%) | 633 (8.3%) | 1999 (11.5%) | 402 (7.2%) | 3615 (8.1%) | 569 (7.5%) | <0.001 | 0.179 |
| Suicide ideations | 179 (1.5%) | 280 (1.3%) | 384 (2.7%) | 362 (3.1%) | 180 (2.4%) | 717 (4.1%) | 77 (1.4%) | 1227 (2.7%) | 165 (2.2%) | <0.001 | 0.173 |
| Anxiety | 1909 (16.1%) | 3617 (16.9%) | 2396 (16.9%) | 2489 (21.3%) | 1343 (17.7%) | 3588 (20.7%) | 1269 (22.6%) | 9231 (20.6%) | 1606 (21.2%) | <0.001 | 0.165 |
| Sleep disorder | 2185 (18.5%) | 2451 (11.4%) | 3539 (25.0%) | 2388 (20.4%) | 1246 (16.4%) | 3385 (19.5%) | 702 (12.5%) | 8325 (18.6%) | 1332 (17.6%) | <0.001 | 0.358 |
| Discontinued | 10,303 (87.1%) | 19,470 (90.8%) | 11,118 (78.5%) | 9045 (77.3%) | 6421 (84.4%) | 15206 (87.5%) | 4925 (87.6%) | 37,222 (83.0%) | 6310 (83.5%) | <0.001 |
†
Medians compared using a Kruskal-Wallis test.
ADHD: Attention-deficit/hyperactivity disorder; SD: Standard devitaion; unk.: Unknown.